Valuation: Norda ASA

Market Cap 513M 53.11M 46.72M 43.34M 39.96M 74.46M 5.1B 75.97M 516M 202M 2.52B 200M 195M 8.68B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.36M 24.07M 22.32M 20.58M 38.36M 2.63B 39.14M 266M 104M 1.3B 103M 101M 4.47B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.65%
6 months+6.67%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 46.28M
+2.08%-1.48%-1.34%+14.07% 46.86B
-0.61%+1.03%+396.16%+643.07% 40.23B
0.00%+4.45%+11.81%+60.81% 36.23B
+2.48%+3.37%+7.05%-8.08% 34.72B
+0.62%+1.65%+5.41%+43.89% 27.89B
-2.00%+9.60%+31.71%+129.76% 16.79B
-0.17%-2.90% - - 16.74B
+0.78%-4.78%-2.68%+9.96% 13.12B
+1.82%-0.72%-9.75%-33.31% 12.7B
Average +0.65%+1.02%+49.60%+107.88% 24.53B
Weighted average by Cap. +0.71%+1.05%+74.69%+138.10%

Financials

2023 2024
Net sales 86.92M 9M 7.91M 7.34M 6.77M 12.61M 865M 12.87M 87.32M 34.16M 426M 33.84M 33.11M 1.47B 372M 38.49M 33.85M 31.4M 28.95M 53.96M 3.7B 55.05M 374M 146M 1.82B 145M 142M 6.29B
Net income 31.17M 3.23M 2.84M 2.63M 2.43M 4.52M 310M 4.62M 31.32M 12.25M 153M 12.14M 11.88M 527M 126M 13.04M 11.47M 10.64M 9.81M 18.28M 1.25B 18.65M 127M 49.5M 618M 49.04M 47.98M 2.13B
Net Debt -311M -32.21M -28.34M -26.28M -24.24M -45.16M -3.1B -46.08M -313M -122M -1.53B -121M -119M -5.27B -249M -25.75M -22.65M -21.01M -19.37M -36.1M -2.47B -36.84M -250M -97.79M -1.22B -96.87M -94.79M -4.21B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock